GENinCode specializes in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode products combine genetic and clinical data to risk assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease.

Our products help inform patients of their health risk enabling them to make behavioural or ‘lifestyle’ changes whilst providing doctors with greater genetic insight and clinical information to determine the most effective treatment pathway (precision medicine).

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset.

With over 15 years research and development in cardiovascular health genomics GENinCode has amassed a deep knowledge and understanding of the interactions between a patient’s genetic profile, lifestyle and clinical risk factors.

GENinCode risk assessment models are based on our in-house developed algorithms and machine learning which allows us to accurately measure and assess a patients clinical and genetic risk.

This innovative approach to precision health is underpinned by our extensive clinical and genotypic datasets, combined with our powerful bioinformatics capability.

We are proud of our extensive and growing international research collaborations with leading scientific teams and expanding list of globally leading publications.

GENinCode test products have been developed to help physicians make improved clinical decisions.

By delivering comprehensive risk assessment we are able to stratify patients and identify the most appropriate treatment pathways aligned with clinical guidelines to ensure optimal outcome.